---
title: "Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285371618.md"
description: "Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Trevi Therapeutics (TRVI) with a price target of $18.00. The analyst has an average return of 17.1% and a success rate of 50.79% on her stock recommendations. The overall analyst consensus for Trevi Therapeutics is a Strong Buy, with an average price target of $22.14."
datetime: "2026-05-06T11:46:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285371618.md)
  - [en](https://longbridge.com/en/news/285371618.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285371618.md)
---

# Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Trevi Therapeutics, with a price target of $18.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Viking Therapeutics, and RegenXBio. According to TipRanks, Samimy has an average return of 17.1% and a 50.79% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevi Therapeutics with a $22.14 average price target.

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI](https://longbridge.com/en/news/295765971.md)
- [Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position](https://longbridge.com/en/news/295837729.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages](https://longbridge.com/en/news/283624419.md)
- [Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts](https://longbridge.com/en/news/294479110.md)